Joe Rogan has joined the growing tribe of teetotalers. On a recent episode of “The Joe Rogan Experience,” the podcaster, 57, said he has given up drinking alcohol. “I think I’m done,” he said. “For no reason, other than that, it’s not good for you.” ALCOHOL LINKED TO BRAIN DAMAGE FOR HEAVY DRINKERS, STUDY FINDS … Read more
Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company’s stock price slid over eight percent on Thursday, after its main competitor in the space, US-based pharmaceutical company Eli Lilly, announced promising Phase 3 trial results for its GLP-1 pill orforglipron, which … Read more
New research being presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that women are much more aware of and knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide).
(NewsNation) — Eli Lilly announced Thursday its experimental weight-loss pill passed its first late-stage trial among patients with diabetes, delivering on the company’s promise to lower blood sugar and body weight like other GLP-1 drugs such as Ozempic and Wegovy. Lilly’s Phase 3 trial showed that Type 2 diabetes patients lost an average of 16 pounds, or nearly … Read more
Dr. Mark Epstein, a New York plastic surgeon, said about 10% of his clients are male. Dr. Mark Epstein/Dimensions/Getty Images More men are getting cosmetic treatments and anti-aging procedures. A plastic surgeon in New York said he’s seen an uptick in male clients. He shared the most popular treatments requested by men, from fillers to … Read more
Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to move production inside the country’s borders. Read more…
A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for individuals living with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments.
As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal policy In early April, CMS rejected a Biden-era proposal to allow Medicare coverage of GLP-1 medications when prescribed solely for weight loss. Medicare … Read more
A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.
Yes, according to a randomized trial of semaglutide in a population with type 2 diabetes.